Allakos Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ALLK Nasdaq 2834 www.allakos.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Allakos Inc.

3 US Penny Stocks Under $200M Market Cap To Watch - Nov 29th, 2024 1:12 pm
All You Need to Know About Allakos (ALLK) Rating Upgrade to Buy - Nov 11th, 2024 5:00 pm
Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results - Nov 6th, 2024 9:02 pm
3 US Penny Stocks With Market Caps Larger Than $50M - Oct 22nd, 2024 1:09 pm
Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers - Oct 10th, 2024 8:02 pm
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results - Aug 7th, 2024 8:02 pm
Can Allakos (NASDAQ:ALLK) Afford To Invest In Growth? - Jul 23rd, 2024 12:33 pm
Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile - Jun 25th, 2024 8:02 pm
Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria - May 28th, 2024 11:02 am
Allakos Inc. Reports Increased Losses in Q1 2024, Misses Analyst Earnings Predictions - May 10th, 2024 8:02 pm
Allakos Provides Business Update and Reports First Quarter 2024 Financial Results - May 9th, 2024 8:02 pm
With 55% ownership of the shares, Allakos Inc. (NASDAQ:ALLK) is heavily dominated by institutional owners - May 3rd, 2024 10:59 am
Allakos (ALLK): Strong Industry, Solid Earnings Estimate Revisions - Apr 4th, 2024 12:36 pm
Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4 - Mar 16th, 2024 9:31 am
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results - Mar 14th, 2024 8:02 pm
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024 - Feb 26th, 2024 12:02 pm
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition - Feb 12th, 2024 12:02 pm